A Single-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Ibudilast (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Biomarker; Pharmacodynamics; Proof of concept
- Sponsors MediciNova
- 10 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated